Aclaris Therapeutics ACRS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Contract Research | $537K— | —— | —— | —— | $445K-29.9% | |
| Dermatology Therapeutics | $1.46M+83.5% | $795K-71.7% | $2.81M+111% | $1.34M+32.2% | $1.01M-88.3% | |
| Research And Development Project Spend by Product | ||||||
| Drug Candidate Ati052 | $3.18M-0.6% | $3.2M+74.2% | $1.84M+29.5% | $1.42M+129% | $619K+30.7% | |
| Drug Candidate Ati2138 | $491K-6.7% | $526K-64.2% | $1.47M+31.4% | $1.12M-38.2% | $1.81M-31.7% | |
| Drug Candidate Ati9494 | $2.23M— | —— | —— | —— | $678K+14.9% | |
| Drug Candidate Bosakitug | $3.14M-31.0% | $4.55M+48.7% | $3.06M+7.6% | $2.85M-15.9% | $3.38M+4,427% | |
| Drug Discovery Platform | $1.44M— | —— | $2.34M+44.4% | $1.62M+143% | $668K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aclaris Therapeutics break its business down?
- Aclaris Therapeutics (ACRS) reports revenue by product across 2 parts — Contract Research and Dermatology Therapeutics. Each is extracted from the segment footnotes and tracked over time.
- Where does Aclaris Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aclaris Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
